reports
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B share...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
VOLV B VOLVO AB CLASS B
WRT1V WARTSILA OYJ ABP
ABB ABB LTD.
SAND SANDVIK AB
TREL B TRELLEBORG AB CLASS B
MOCORP METSO OUTOTEC OYJ
ASSA B ASSA ABLOY AB CLASS B
SKF B SKF AB CLASS B
HPOL B HEXPOL AB CLASS B
ALFA ALFA LAVAL AB
MTRS B MUNTERS GROUP
HEXA B HEXAGON AB
EPI A EPIROC AB
NIBE B NIBE INDUSTRIER AB
ATCO A ATLAS COPCO AB
ALIV SDB AUTOLIV INC.
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...
- Julian Dobrovolschi
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/15/2024
With 71% of the companies in the Stoxx 600 having released their Q1 2024 results, the picture at this stage is encouraging, with 58% of positive surprises on results. Materials and financials were the sectors that delivered the most positive surprises. If the Q4 2023 earnings season put an end to a downward revision of EPS, the Q1 2024 earnings season has triggered the start of an upward EPS revision, more markedly in the US than in Europe. In terms of sectors, re-rating effects conti...
VIE VEOLIA ENVIRONNEMENT SA
TKA THYSSENKRUPP AG
FGR EIFFAGE SA
HNR1 HANNOVER RUECK SE
GBF BILFINGER SE
CPG COMPASS GROUP PLC
MRK MERCK KGAA
EOAN E.ON SE
ALO ALSTOM SA
GRF GRIFOLS S.A. CLASS A
RWE RWE AG
LEG LEG IMMOBILIEN AG
ASSA B ASSA ABLOY AB CLASS B
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
WLN WORLDLINE SA
GRF.P GRIFOLS S.A. PREF CLASS B
HLAG HAPAG-LLOYD AG
REY REPLY S.P.A.
NEXI NEXI S.P.A.
AZE AZELIS GROUP NV
NCH2 THYSSENKRUPP NUCERA AG & CO.
- Carole Braudeau
- Julian Dobrovolschi
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/05/2024
Alors que 71% des sociétés du Stoxx 600 ont publié, le bilan est à ce stade positif avec 58% de surprises positives sur les résultats. Matériaux et Financières sont les secteurs ayant apporté le plus de surprises positives. Le consensus – qui avait stoppé sa baisse durant les publications T4-23, est désormais reparti à la hausse, plus nettement aux Etats-Unis qu’en Europe. Sectoriellement, les effets de rerating ont continué de dominer les révisions de BPA. - ...
VIE VEOLIA ENVIRONNEMENT SA
TKA THYSSENKRUPP AG
FGR EIFFAGE SA
HNR1 HANNOVER RUECK SE
GBF BILFINGER SE
CPG COMPASS GROUP PLC
MRK MERCK KGAA
EOAN E.ON SE
ALO ALSTOM SA
GRF GRIFOLS S.A. CLASS A
RWE RWE AG
LEG LEG IMMOBILIEN AG
ASSA B ASSA ABLOY AB CLASS B
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
WLN WORLDLINE SA
GRF.P GRIFOLS S.A. PREF CLASS B
HLAG HAPAG-LLOYD AG
REY REPLY S.P.A.
NEXI NEXI S.P.A.
AZE AZELIS GROUP NV
NCH2 THYSSENKRUPP NUCERA AG & CO.
- Juan Ros-Padilla
Grifols B : Q1 EBITDA a shade below, earnings significantly so. FY 202...
>Top line momentum deteriorated, partly explained by a tough Diagnostic comps. - Sales grew by +4% or +6% cc (vs +9% cc in Q4) to € 1.8bn, slightly below our numbers yet more aligned with the consensus. Biopharma posted +8% y-o-y growth or +9% cc (vs +10% cc in Q4) to € 1.5bn driven by a very solid trend on IG (+13%) and more specifically the SCIG (+62%cc explaining c.5% of IG sales) which were partly offset by a soft performance from Albumin (+7% cc) and Alpha1/other...
- Juan Ros-Padilla
Grifols A : Q1 EBITDA a shade below, earnings significantly so. FY 202...
>Top line momentum deteriorated, partly explained by a tough Diagnostic comps. - Sales grew by +4% or +6% cc (vs +9% cc in Q4) to € 1.8bn, slightly below our numbers yet more aligned with the consensus. Biopharma posted +8% y-o-y growth or +9% cc (vs +10% cc in Q4) to € 1.5bn driven by a very solid trend on IG (+13%) and more specifically the SCIG (+62%cc explaining c.5% of IG sales) which were partly offset by a soft performance from Albumin (+7% cc) and Alpha1/other...
Hermès International: Shares and voting rights as of 30 April 2024
Hermès International: Shares and voting rights as of 30 April 2024 RELEASE Paris, May 14, 2024 INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPRISING THE SHARE CAPITAL In accordance with the provisions of Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF), Hermès international publishes each month, before the 15th day of the following month, the total number of voting rights and the number of shares comprising the share capital if they have varied from thos...
Hermès International: actions et droits de vote au 30 avril 2024
Hermès International: actions et droits de vote au 30 avril 2024 COMMUNIQUÉ Paris, le 14 mai 2024 INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL Conformément aux dispositions de l’article L. 233-8 du Code de commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (AMF), Hermès international publie chaque mois, avant le 15 du mois suivant, le nombre total de droits de vote et le nombre d’actions composant le capital social s’ils ont variés par rapport à ceux publiées antérieurement.DateNombre d’actions com...
- Carole Braudeau
- Stephane Beyazian
- Stephane Beyazian
- Carole Braudeau
Morning Crédit 14/05/2024
Iliad abonde les obligations Iliad Holding 2031 à hauteur de 150 m EUR et 200 m USD Grifols : S&P confirme le rating corporate B avec une perspective stable (vs. B/cw negative) Delivery Hero : cession de foodpanda à Uber pour 950 m USD + augmentation de capital réservée de 300 m USD>...
- Damien Choplain
- Martial Descoutures
Novo Nordisk : Mim8 officially in competition with Hemlibra
>Positive results for the FRONTIER2 trial evaluating Mim8 in haemophilia A - Novo reported yesterday evening the clinical results of its phase 3 trial evaluating Mim8 in haemophilia A. Some 250 patients with haemophilia A and with or without inhibitors were included in the trial. The primary endpoint was to demonstrate control of bleeding episodes. Note that this trial was structured between 2 patient cohorts: one with no initial prophylaxis treatment treatment (n=57)...
- Damien Choplain
- Martial Descoutures
Novo Nordisk : Mim8 officiellement en concurrence avec Hemlibra
>Résultats positifs de l’essai FRONTIER2 évaluant Mim8 en hémophilie A - Novo publiait hier soir les résultats cliniques de son essai de phase 3 évaluant Mim8 en hémophilie A. 250 patients atteints d’hémophilie A présentant ou non des inhibiteurs étaient inclus dans cet essai. Le critère primaire est de démontrer un contrôle des saignements. Il faut noter que cet essai a été structuré entre 2 cohortes de patients : l’une ayant initialement aucune prophylaxie (n=57) et...
Hermes International: 1 director
A director at Hermes International sold 2,500 shares at 2,331.960EUR and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superi...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatm...
- Bruno Cavalier
- Louis Boujard
- CFA
- Philippe Ourpatian
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SDF K+S AG
G ASSICURAZIONI GENERALI S.P.A.
01913 PRADA S.P.A.
CRG CRH PLC
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.